Send me a link:

*Text messaging rates may apply.

 Dow Up0.17% Nasdaq Up0.44%

Aratana Therapeutics, Inc. (PETX)

14.57 Down 0.21(1.42%) Jul 11, 4:00PM EDT
ProfileGet Profile for:
Aratana Therapeutics, Inc.
1901 Olathe Boulevard
Kansas City, KS 66103
United States - Map
Phone: 913-951-2132

Index Membership:N/A
Full Time Employees:25

Business Summary 

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Aratana Therapeutics, Inc.

Key Executives 
Dr. Steven St. Peter M.D., 48
Co-Founder, Chief Exec. Officer, Pres and Director
Mr. Craig A. Tooman MBA, 48
Chief Financial Officer, Principal Accounting Officer and Treasurer
Dr. Linda Rhodes VMD, Ph.D., 64
Chief Scientific Officer
Dr. Ernst Heinen D.V.M., Ph.D., 51
Chief Devel. Officer
Mr. Erick Lucera ,
VP of Corp. Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders